4D Molecular Therapeutics(US:FDMT)2025-05-08 20:16Financial Performance - 4D Molecular Therapeutics reported a net loss of $48.0 million for Q1 2025, compared to a net loss of $32.4 million in Q1 2024, reflecting an increase in operational expenses[12]. - General and administrative expenses rose to $12.9 million in Q1 2025 from $10.3 million in Q1 2024, driven by increased professional services[12]. - The accumulated deficit increased to $624.2 million as of March 31, 2025, compared to $576.2 million at the end of 2024[20]. Research and Development - Research and development expenses increased to $40.7 million in Q1 2025 from $27.9 million in Q1 2024, primarily due to the initiation of the Phase 3 clinical trial for 4D-150 in wet AMD[11]. - The first patients were enrolled in the Phase 3 clinical trial (4FRONT-1) for 4D-150 in wet AMD, with over 50 clinical trial sites currently open[5]. - Topline data from both Phase 3 trials (4FRONT-1 and 4FRONT-2) for 4D-150 is expected in H2 2027[5]. - In a Phase 2b cohort, 4D-150 demonstrated an 83% reduction in injection burden compared to projected on-label aflibercept 2 mg Q8W, with 70% of patients requiring 0-1 supplemental injection[9]. Cash and Funding - The company had $458 million in cash, cash equivalents, and marketable securities as of March 31, 2025, down from $505 million at the end of 2024, expected to fund operations into 2028[10]. - The company has paused significant additional capital allocation for other programs pending financing or partnerships, extending its cash runway into 2028[6]. Regulatory Designations - The company received RMAT designation from the FDA for 4D-150 in diabetic macular edema, adding to previous designations for wet AMD[5].